SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma’s arm gets 11 observations from USFDA for Telangana Formulation facility

07 Feb 2026 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ Unit-III has been inspected by the United States Food and Drug Administration (USFDA). The inspection was conducted from January 27 to February 06, 2026 and concluded with 11 observations. The observations are procedural in nature. The Unit-III is a Formulation manufacturing facility of Eugia Pharma Specialities situated in Telangana. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1382.55 -3.55 (-0.26%)
17-Apr-2026 09:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1685.90
Dr. Reddys Lab 1215.90
Cipla 1227.00
Zydus Lifesciences 938.00
Lupin 2317.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×